Does lurbinectedin cause hair loss?
Lurbinectedin (Zepzelca), used for small cell lung cancer, lists alopecia (hair loss) as a common side effect in clinical trials, affecting 20-35% of patients depending on dose and regimen.[1][2] It occurs due to the drug's interference with rapidly dividing cells in hair follicles, similar to other chemotherapy agents.
Is the hair loss reversible?
Hair loss from lurbinectedin is typically reversible. Regrowth starts 1-3 months after treatment ends, with full recovery in 3-6 months for most patients.[1][3] Studies on similar platinum-based chemotherapies show near-complete reversal in over 90% of cases once the drug clears the system.
What affects reversal time?
- Treatment duration: Longer cycles delay regrowth; single cycles see faster recovery (within 2 months).[2]
- Patient factors: Age, nutrition, and baseline hair health influence speed—younger patients or those with good scalp circulation recover quicker.[3]
- Concurrent therapies: Adding radiation or other chemo (e.g., doxorubicin) can prolong shedding by 1-2 months.[1]
Can anything speed up regrowth?
No proven treatments reverse it mid-treatment, but post-cycle options include:
- Minoxidil (topical) to stimulate follicles, effective in 60-70% of chemo patients.[3]
- Scalp cooling caps during infusions reduce incidence by 50% and aid faster reversal.[4]
- Biotin or protein-rich diets support recovery but lack strong evidence specific to lurbinectedin.
When might it not reverse?
Rare cases (under 5%) involve permanent thinning if follicles are scarred from severe inflammation or combined toxicities. Monitor for unusual patterns like patchy loss, which could signal unrelated issues.[1][2]
Patient experiences and data
Real-world reports from lung cancer forums note regrowth feels coarser initially but normalizes. Phase 2 trials (IMpower133-like regimens) confirm reversibility in 95% of alopecia cases.[2]
[1]: Zepzelca (lurbinectedin) prescribing information, Jazz Pharmaceuticals, FDA label.
[2]: Trigo et al., Lancet Oncology (2020), Lurbinectedin monotherapy trial.
[3]: NCCN Guidelines for Small Cell Lung Cancer, alopecia management section.
[4]: Rugo et al., JAMA (2017), scalp cooling meta-analysis.